UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 79

Sortiert nach

Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial

The lancet oncology, 2016-06, Vol.17 (6), p.738-746

2016

Volltextzugriff (PDF)

Medical treatment of elderly patients with breast cancer

Anti-cancer agents in medicinal chemistry, 2013-11, Vol.13 (9), p.1325

2013

Volltextzugriff (PDF)

Weekly docetaxel in the treatment of metastatic breast cancer

Therapeutics and clinical risk management, 2008-10, Vol.4 (5), p.1047-1059

2008

Volltextzugriff (PDF)

Oncology clinical trial termination trends: Analysis across the prior 20 years

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.e13602-e13602

2022

Volltextzugriff (PDF)

Reporting of patient reported outcomes in randomized clinical trials (RCTs) in non-small cell lung cancer (NSCLC) patients (pts)

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.6573-6573

2023

Volltextzugriff (PDF)

Retreatment with anti-EGFR monoclonal antibodies in metastatic colorectal cancer: Systematic review of different strategies

Cancer treatment reviews, 2019-02, Vol.73, p.41-53

2019

Volltextzugriff (PDF)

Sensitivity to Entrectinib Associated With a Novel LMNA-NTRK1 Gene Fusion in Metastatic Colorectal Cancer

JNCI : Journal of the National Cancer Institute, 2016-01, Vol.108 (1), p.1

2016

Volltextzugriff (PDF)

Should cirrhosis change our attitude towards treating non-hepatic cancer?

Liver international, 2012-01, Vol.32 (1), p.21-27

2012

Volltextzugriff (PDF)

Oxaliplatin Immune-Induced Syndrome Occurs With Cumulative Administration and Rechallenge: Single Institution Series and Systematic Review Study

Clinical colorectal cancer, 2016-09, Vol.15 (3), p.213-221

2016

Volltextzugriff (PDF)

Abstract CT005: Final results of the HERACLES trial in HER2-amplified colorectal cancer

Cancer research (Chicago, Ill.), 2017-07, Vol.77 (13_Supplement), p.CT005-CT005

2017

Volltextzugriff (PDF)

Cisplatin and gemcitabine with either vinorelbine or paclitaxel in the treatment of carcinomas of unknown primary site : Results of an Italian multicenter, randomized, phase II study

Cancer, 2006-12, Vol.107 (12), p.2898-2905

2006

Volltextzugriff (PDF)

Regulatory Cytokine Gene Polymorphisms and Risk of Colorectal Carcinoma

Annals of the New York Academy of Sciences, 2006-11, Vol.1089 (1), p.98-103

2006

Volltextzugriff (PDF)

Alka-372-001: First-in-human, phase I study of entrectinib – an oral pan-trk, ROS1, and ALK inhibitor – in patients with advanced solid tumors with relevant molecular alterations

Journal of clinical oncology, 2015-05, Vol.33 (15_suppl), p.2517-2517

2015

Volltextzugriff (PDF)

Cytokine Gene Polymorphisms and Breast Cancer Susceptibility

Annals of the New York Academy of Sciences, 2006-11, Vol.1089 (1), p.104-109

2006

Volltextzugriff (PDF)

Phase 1 open label, dose escalation study of RXDX101, an oral pan-trk, ROS1, and ALK inhibitor, in patients with advanced solid tumors with relevant molecular alterations

Journal of clinical oncology, 2014-05, Vol.32 (15_suppl), p.2502-2502

2014

Volltextzugriff (PDF)

Gemcitabine combined with either pemetrexed or paclitaxel in the treatment of advanced non-small cell lung cancer A randomized phase II SICOG trial

Lung cancer (Amsterdam, Netherlands), 2010-04, Vol.68 (1), p.94-98

2010

Volltextzugriff (PDF)

Cisplatin and gemcitabine with either vinorelbine or paclitaxel in the treatment of carcinomas of unknown primary site

Cancer, 2006-12, Vol.107 (12), p.2898-2905

2006

Volltextzugriff (PDF)

Gemcitabine combined with either pemetrexed or paclitaxel in the treatment of advanced non-small cell lung cancer

Lung cancer (Amsterdam, Netherlands), 2010-04, Vol.68 (1), p.94-98

2010

Volltextzugriff (PDF)

Role of loco-regional treatments for patients with breast cancer liver metastases

Recenti progressi in medicina, 2009-09, Vol.100 (9), p.424

2009

Volltextzugriff (PDF)

Improved resolution power of electrophoretic fractionation of DNA using a voltage gradient "up and down" application

Electrophoresis, 2004-09, Vol.25 (17), p.2932-2934

2004

Volltextzugriff (PDF)

1 – 25 von 79

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(59)
Mit Volltextzugriff
(72)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(3)

Menü

Weitere Dienste

Einstellungen

Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial

Medical treatment of elderly patients with breast cancer

High Circulating Methylated DNA Is a Negative Predictive and Prognostic Marker in Metastatic Colorectal Cancer Patients Treated With Regorafenib

Weekly docetaxel in the treatment of metastatic breast cancer

Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1)

Oncology clinical trial termination trends: Analysis across the prior 20 years

Reporting of patient reported outcomes in randomized clinical trials (RCTs) in non-small cell lung cancer (NSCLC) patients (pts)

Retreatment with anti-EGFR monoclonal antibodies in metastatic colorectal cancer: Systematic review of different strategies

Sensitivity to Entrectinib Associated With a Novel LMNA-NTRK1 Gene Fusion in Metastatic Colorectal Cancer

Should cirrhosis change our attitude towards treating non-hepatic cancer?

Oxaliplatin Immune-Induced Syndrome Occurs With Cumulative Administration and Rechallenge: Single Institution Series and Systematic Review Study

Abstract CT005: Final results of the HERACLES trial in HER2-amplified colorectal cancer

Baseline Characteristics and Outcomes of Cancer Patients Infected with SARS-CoV-2 in the Lombardy Region, Italy (AIOM-L CORONA): A Multicenter, Observational, Ambispective, Cohort Study

Pooled Analysis of Clinical Outcome of Patients with Chemorefractory Metastatic Colorectal Cancer Treated within Phase I/II Clinical Studies Based on Individual Biomarkers of Susceptibility: A Single-Institution Experience

Cisplatin and gemcitabine with either vinorelbine or paclitaxel in the treatment of carcinomas of unknown primary site : Results of an Italian multicenter, randomized, phase II study

Regulatory Cytokine Gene Polymorphisms and Risk of Colorectal Carcinoma

Alka-372-001: First-in-human, phase I study of entrectinib – an oral pan-trk, ROS1, and ALK inhibitor – in patients with advanced solid tumors with relevant molecular alterations

Safety and Antitumor Activity of the Multi-Targeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib (RXDX-101): Combined Results from Two Phase 1 Trials (ALKA-372-001 and STARTRK-1)

Cytokine Gene Polymorphisms and Breast Cancer Susceptibility

Phase 1 open label, dose escalation study of RXDX101, an oral pan-trk, ROS1, and ALK inhibitor, in patients with advanced solid tumors with relevant molecular alterations

Gemcitabine combined with either pemetrexed or paclitaxel in the treatment of advanced non-small cell lung cancer A randomized phase II SICOG trial

Cisplatin and gemcitabine with either vinorelbine or paclitaxel in the treatment of carcinomas of unknown primary site

Gemcitabine combined with either pemetrexed or paclitaxel in the treatment of advanced non-small cell lung cancer

Role of loco-regional treatments for patients with breast cancer liver metastases

Improved resolution power of electrophoretic fractionation of DNA using a voltage gradient "up and down" application

Suchergebnisse filtern